276 related articles for article (PubMed ID: 11711528)
1. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Zannad F; Dousset B; Alla F
Hypertension; 2001 Nov; 38(5):1227-32. PubMed ID: 11711528
[TBL] [Abstract][Full Text] [Related]
2. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Zannad F; Alla F; Dousset B; Perez A; Pitt B
Circulation; 2000 Nov; 102(22):2700-6. PubMed ID: 11094035
[TBL] [Abstract][Full Text] [Related]
3. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients.
MacFadyen RJ; Barr CS; Struthers AD
Cardiovasc Res; 1997 Jul; 35(1):30-4. PubMed ID: 9302344
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
[TBL] [Abstract][Full Text] [Related]
5. Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure.
Zannad F; Radauceanu A
Heart Fail Rev; 2005 Jan; 10(1):71-8. PubMed ID: 15947894
[TBL] [Abstract][Full Text] [Related]
6. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
[TBL] [Abstract][Full Text] [Related]
7. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
Brilla CG; Schencking M; Scheer C; Rupp H
Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
[TBL] [Abstract][Full Text] [Related]
8. Role of intracardiac renin-angiotensin-aldosterone system in extracellular matrix remodeling.
Lijnen PJ; Petrov VV
Methods Find Exp Clin Pharmacol; 2003 Sep; 25(7):541-64. PubMed ID: 14571285
[TBL] [Abstract][Full Text] [Related]
9. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
Bauersachs J; Fraccarollo D
Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
[TBL] [Abstract][Full Text] [Related]
10. Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy.
Maron MS; Chan RH; Kapur NK; Jaffe IZ; McGraw AP; Kerur R; Maron BJ; Udelson JE
Am J Med; 2018 Jul; 131(7):837-841. PubMed ID: 29604289
[TBL] [Abstract][Full Text] [Related]
11. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.
Tsutamoto T; Wada A; Maeda K; Mabuchi N; Hayashi M; Tsutsui T; Ohnishi M; Sawaki M; Fujii M; Matsumoto T; Matsui T; Kinoshita M
J Am Coll Cardiol; 2001 Apr; 37(5):1228-33. PubMed ID: 11300427
[TBL] [Abstract][Full Text] [Related]
12. ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES).
Pitt D
Eur Heart J; 1995 Dec; 16 Suppl N():107-10. PubMed ID: 8682055
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone in congestive heart failure.
Soberman JE; Weber KT
Curr Hypertens Rep; 2000 Oct; 2(5):451-6. PubMed ID: 10995520
[TBL] [Abstract][Full Text] [Related]
14. Aldosterone antagonism and congestive heart failure: a new look at an old therapy.
Thohan V; Torre-Amione G; Koerner MM
Curr Opin Cardiol; 2004 Jul; 19(4):301-8. PubMed ID: 15218387
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
[TBL] [Abstract][Full Text] [Related]
16. [The role of aldosterone-antagonists in the treatment of congestive heart failure].
Fügedi K
Orv Hetil; 2005 Apr; 146(14):645-8. PubMed ID: 15889538
[TBL] [Abstract][Full Text] [Related]
17. Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study.
Ferreira JP; Duarte K; Montalescot G; Pitt B; de Sa EL; Hamm CW; Flather M; Verheugt F; Shi H; Turgonyi E; Orri M; Rossignol P; Vincent J; Zannad F
Clin Res Cardiol; 2018 Jan; 107(1):49-59. PubMed ID: 28852839
[TBL] [Abstract][Full Text] [Related]
18. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy.
Ramires FJ; Mansur A; Coelho O; Maranhão M; Gruppi CJ; Mady C; Ramires JA
Am J Cardiol; 2000 May; 85(10):1207-11. PubMed ID: 10802002
[TBL] [Abstract][Full Text] [Related]
19. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients.
Orea-Tejeda A; Colín-Ramírez E; Castillo-Martínez L; Asensio-Lafuente E; Corzo-León D; González-Toledo R; Rebollar-González V; Narváez-David R; Dorantes-García J
Rev Invest Clin; 2007; 59(2):103-7. PubMed ID: 17633796
[TBL] [Abstract][Full Text] [Related]
20. The endothelin-aldosterone axis and cardiovascular diseases.
Rossi GP; Cavallin M; Nussdorfer GG; Pessina AC
J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S49-52. PubMed ID: 11811378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
